Eisai

Eisai files Leqembi in Korea, as US prospects firm up
Eisai files Leqembi in Korea, as US prospects firm up
Pharmaphorum
Eisai
Biogen
Leqembi
Alzheimer's disease
South Korea
Asia
Flag link:
Ahead of key meeting, FDA appears open to full approval of Alzheimer’s drug Leqembi
Ahead of key meeting, FDA appears open to full approval of Alzheimer’s drug Leqembi
BioPharma Dive
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Forbes
Alzheimer's disease
FDA
insurance
Leqembia
Biogen
Eisai
Eli Lilly
donanemab
Flag link:
FDA Removes Expert with Ties to Eisai, Biogen from Leqembi Adcomm
FDA Removes Expert with Ties to Eisai, Biogen from Leqembi Adcomm
BioSpace
FDA
Biogen
Eisai
Alzheimer's disease
Leqembi
Flag link:
PhRMA cries foul on CMS' registry approach for Alzheimer's disease drugs
PhRMA cries foul on CMS' registry approach for Alzheimer's disease drugs
Fierce Pharma
Biogen
Eisai
Alzheimer's disease Leqembi
CMS
PhRMA
Flag link:
Medicare outlines plan to expand coverage for costly new Alzheimer’s drugs
Medicare outlines plan to expand coverage for costly new Alzheimer’s drugs
Washington Post, DC
Medicare
Alzheimer's disease
Eisai
Biogen
Leqembi
Flag link:
The Alzheimer's pipeline is as strong as ever. Now, we just need the patients
The Alzheimer's pipeline is as strong as ever. Now, we just need the patients
Fierce Biotech
Alzheimer's disease
patients
clinical trials
Biogen
Eisai
Eli Lilly
Flag link:
Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
Merck and Eisai tease results for renal carcinoma treatment
Merck and Eisai tease results for renal carcinoma treatment
Clinical Trials Arena
Merck
Eisai
ASCO 2023
Lenvima
Keytruda
renal cell carcinoma
Flag link:
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
BioSpace
Eisai
Biogen
Alzheimer's disease
Leqembi
amyloid beta
Flag link:
JAMA: Leqembi could cost Medicare up to $5B per year
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
Flag link:
Eisai Pays up to $2B for ADC Bearing Its Halaven as Payload
Eisai Pays up to $2B for ADC Bearing Its Halaven as Payload
BioSpace
Eisai
Bliss Biopharmaceutical
clinical trials
antibody-drug conjugate
Halaven
Flag link:
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
BioSpace
Merck
Keytruda
Eisai
Lenvima
melanoma
clinical trials
cancer
colorectal cancer
Flag link:
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Fierce Pharma
Eisai
Leqembi
FDA
CMS
Alzheimer's disease
Flag link:
Alzheimer's Association campaigns for broader Leqembi coverage: report
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
VHA
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
Flag link:
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Eisai
Biogen
Alzheimer's disease
Leqembi
Flag link:
FDA sets July decision date for full approval of Leqembi
FDA sets July decision date for full approval of Leqembi
BioSpace
Eisai
Biogen
Alzheimer's disease
Leqembi
FDA
lecanemab
Flag link:
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
Fierce Pharma
ICER
Eisai
Leqembi
drug pricing
Alzheimer's disease
Flag link:
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Flag link:

Pages